New medicijnenmix makes tb treatment more successful
In the coming years, expect the tb-experts a number of important successes in the fight against the disease.
Both in the field of scientific research as the treatment is in the recent time a lot of progress, says the KNCV Tuberculosefonds.
New rapid diagnostics, and a new mix of medications to make the treatment of (mdr) tuberculosis is significantly shorter and more successful. In a still ongoing research we found all forty patients who six months were treated, cured; thirty of the 31 patients who are now about half a year later followed remained disease-free, a breakthrough.
KNCV Tuberculosefonds doing since the beginning of this year, research in Kyrgyzstan and Tajikistan. MDR-tb and XDR-tb forms in these former soviet republics is a major problem. The expectation is that it is a relatively new drug bedaquiline and a shortened behandelregime of nine months the treatment of drug-resistant tuberculosis may significantly improve. In addition to this, new treatment is better tolerated.
“The messages from the two countries are very promising,” says Susan van den Hof of KNCV Tuberculosefonds. “Patients are now a month busy with the treatment. They that first not get out of bed, walk yourself around. Also give patients that they suffered less from side effects. We can not yet say how many more patients now will be cured of this often deadly disease. But we can already say that most of the patients after a month if not more contagious. This is a sign that the treatment is successful.”
Risk for the Netherlands
Tuberculosis is the infectious disease with the most fatalities worldwide. According to the world health organization (WHO) in 2015, 10.4 million people have the disease and died there 1.8 million. In the same year were estimated 580.000 people MDR-tb, and about 40,000 people have XDR-tb.
Although tuberculosis especially outside of the rich countries is a problem, there is also a danger for the Netherlands. When multi-drug resistant tuberculosis are not well internationally is addressed, can outbreak of the disease in the future in the Netherlands also have major consequences.
“The netherlands is not an island, and the tb knows no borders,” says Kitty van Weezenbeek, executive director of KNCV Tuberculosefonds. “Therefore, it is essential that we join forces to give the disease to address where most of the victims are. Only with a global approach, we can prevent this age-old disease, in particular the drug-resistant variant, the us still beats.”
According to a this week released report of the world health organization Europe (WHO Europe) and the European Centre for Disease Prevention and Control (ECDC) continues, despite the decrease in the number of tb patients number of hiv patients with tuberculosis and the number of patients with multidrug-resistant tuberculosis rising. One in five new drug-resistant cases occur in Europe.
Symptoms of tb include chest pain and prolonged cough in which phlegm is coughed up. Some patients cough up blood, and in very rare cases, the infection may be a pulmonary artery affected, causing a large hemorrhage occurs.